Cara Financial Statements From 2010 to 2024
CARA Stock | USD 0.67 0 0.30% |
Gross Profit -56.1 M | Market Capitalization 38.7 M | Enterprise Value Revenue 12.0452 | Revenue 21 M | Earnings Share (2.19) |
Cara Therapeutic Total Revenue |
|
Check Cara Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cara main balance sheet or income statement drivers, such as Depreciation And Amortization of 498.1 K, Interest Expense of 1 M or Selling General Administrative of 15.7 M, as well as many exotic indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or PTB Ratio of 0.67. Cara financial statements analysis is a perfect complement when working with Cara Therapeutic Valuation or Volatility modules.
Cara | Select Account or Indicator |
Cara Therapeutic Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cara Therapeutic Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cara Therapeutic Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cara Therapeutic Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Cara Fundamental Market Drivers
Cash And Short Term Investments | 101.2 M |
Cara Upcoming Events
4th of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
About Cara Therapeutic Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Cara Therapeutic income statement, its balance sheet, and the statement of cash flows. Cara Therapeutic investors use historical funamental indicators, such as Cara Therapeutic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cara Therapeutic investors may use each financial statement separately, they are all related. The changes in Cara Therapeutic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cara Therapeutic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cara Therapeutic Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cara Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Current Deferred Revenue | 25.6 M | 26.9 M | |
Cost Of Revenue | 6.4 M | 6.1 M | |
Total Revenue | 21 M | 25.2 M | |
Stock Based Compensation To Revenue | 0.65 | 0.62 | |
Sales General And Administrative To Revenue | 1.32 | 1.25 | |
Research And Ddevelopement To Revenue | 5.17 | 4.91 | |
Capex To Revenue | (0.11) | (0.12) | |
Revenue Per Share | 0.39 | 0.42 | |
Ebit Per Revenue | (5.79) | (6.08) |
Pair Trading with Cara Therapeutic
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cara Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cara Therapeutic will appreciate offsetting losses from the drop in the long position's value.Moving together with Cara Stock
0.86 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
0.78 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.69 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
Moving against Cara Stock
0.48 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cara Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cara Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cara Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cara Therapeutic to buy it.
The correlation of Cara Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cara Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cara Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cara Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Cara Therapeutic Correlation against competitors. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.